Digital biomarkers can change dementia tracking: IISc professor

Prof KVS Hari, director of the Centre for Brain Research at IISc Bengaluru, emphasized digital biomarkers for early detection and prevention of dementia. He noted that India's rapidly aging population makes dementia a major public health challenge. The centre focuses on data collection and AI to understand disease progression in the Indian context.

Prof KVS Hari, director of the Centre for Brain Research (CBR) at IISc Bengaluru, discussed dementia research in an interview with the Indian Express. Funded initially by a gift from the Pratiksha Trust of Infosys co-founder Kris Gopalakrishnan, CBR studies the aging brain and related disorders. Hari stated, 'By 2030, India will have around 340 million elderly, with roughly 7.4% affected by dementia.' In India, dementia is often dismissed as normal aging, receiving limited policy attention.

Dementia, encompassing Alzheimer's, Parkinson's, and vascular types, progresses 15-20 years before clinical diagnosis. Hari noted that despite decades of animal model research, no cure exists for Alzheimer's; the 2024-approved drug only delays onset by six to eight months. Thus, CBR focuses on human-derived early biomarkers using multimodal data, emphasizing lifestyle interventions like exercise, diet, and sleep.

Western drugs may not fully apply due to Indian genetics. In India, diabetes and hypertension onset a decade earlier, accelerating dementia. CBR launched an urban cohort in 2015 with 1,000 Bengaluru residents, involving annual assessments: clinical evaluations, blood samples, cognitive tests, MRI, OCT, audiometry, gait analysis, and more. A rural cohort in Kolar district started in 2018, targeting 10,000 participants with biennial follow-ups; first-round enrollment completed in February 2025.

Challenges include participant retention in longitudinal studies and building diverse datasets. Opportunities lie in non-pharmacological interventions, personalized lifestyle protocols, and digital tools like apps monitoring speech and gait. Blood-based plasma protein biomarkers and wearables enable continuous screening. Hari said, 'AI can detect patterns in multi-modal data that other methods miss.' Startups are developing speech-based diagnostics and portable low-field MRI. CBR is pushing for national cognitive data repositories to address fragmented health data.

Awọn iroyin ti o ni ibatan

Realistic split-image illustration showing obesity-linked faster rise in Alzheimer’s blood biomarkers versus normal weight, highlighting blood tests detecting changes earlier than brain scans.
Àwòrán tí AI ṣe

Obesity linked to faster rise in Alzheimer’s blood biomarkers, study finds

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

New research finds that blood biomarkers associated with Alzheimer’s disease increase significantly faster in people with obesity than in those without. Drawing on five years of data from 407 volunteers, the study suggests that blood tests can detect obesity‑related changes earlier than brain scans, underscoring obesity as a major modifiable risk factor for Alzheimer’s.

Scientists at Brown University have identified a subtle brain activity pattern that can forecast Alzheimer's disease in people with mild cognitive impairment up to two and a half years in advance. Using magnetoencephalography and a custom analysis tool, the researchers detected changes in neuronal electrical signals linked to memory processing. This noninvasive approach offers a potential new biomarker for early detection.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

A large study published in Neurology finds that impaired kidney function is linked to higher levels of Alzheimer’s biomarkers in the blood, without increasing overall dementia risk. However, among people who already have elevated biomarker levels, poor kidney health may hasten when dementia symptoms appear, underscoring the need to factor kidney function into interpretation of Alzheimer’s blood tests.

A recently recognized form of dementia, known as LATE, is reshaping understanding of cognitive decline in the elderly, with rising diagnoses and guidelines for doctors published this year. It is estimated to affect about one-third of people aged 85 or older and 10% of those aged 65 or older, often mistaken for Alzheimer's. Experts emphasize the need for a broader range of treatments for this condition.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

Researchers at McMaster University and the Population Health Research Institute report that simple retinal scans, combined with genetic and blood data, may offer a non-invasive window into cardiovascular health and biological aging. An analysis of more than 74,000 people linked simpler eye-vessel patterns to higher heart-disease risk and faster aging. The study, published October 24, 2025, in Science Advances, points to potential early-detection tools that remain under investigation.

Katie Wells, founder of Wellness Mama, shares insights from her personalized health risk assessment using AI-driven tools, highlighting how lifestyle factors can significantly influence chronic disease risks. The assessment, powered by data from over 10,000 studies, showed her cancer risk below the population average despite family history. It underscores a shift toward proactive prevention over reactive medicine.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

Scientists in the U.K. and Canada report the first direct visualization and measurement of alpha‑synuclein oligomers—the small protein clusters long suspected of triggering Parkinson’s—in human brain tissue. Using an ultra‑sensitive imaging method, the team found these clusters were larger and more numerous in Parkinson’s than in age‑matched controls, a result published in Nature Biomedical Engineering that may help guide earlier diagnosis and targeted therapies.

 

 

 

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ